XNAS
FLGC
Market cap13mUSD
Jul 28, Last price
0.61USD
1D
-1.54%
1Q
0.98%
IPO
-99.35%
Name
Flora Growth Corp
Chart & Performance
P/E
—
P/S
0.23
EPS
—
Div Yield, %
—
Shrs. gr., 5y
22.82%
Rev. gr., 5y
%
Revenues
60m
-21.78%
Net income
-16m
L-72.11%
CFO
-5m
L-40.07%
Profile
Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products to pharmacies, medical clinics, and cosmetic companies worldwide. It cultivates, processes, and supplies medicinal-grade cannabis oil, and cannabis derived medical and wellness products; offers skincare and beauty products; develops plant-based and medical-grade pharmaceuticals, phytotherapeutics, and dietary supplements; and designs and markets loungewear made from hemp-derived fabric and materials. The company also manufactures, distributes, and retails cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; lifestyle wellness products, including edibles, bath and body, pets, sports recovery, etc.; provides cannabis consumption accessories, personal storage, and travel accessories for vape and dry herb categories; and offers juices, exotic fruits coated with chocolate, and chocolate bars, as well as dried fruits, beans, and pulp from Amazonian fruits in supermarkets, discount retailers, coffee shops, restaurants, and airports. In addition, it engages in the manufacturing, promotion, and distribution of beverage products; manufacture and sale of product formulations for pain relief; and development of pharmaceutical cannabinoid formula for the prevention of Sars-Cov-2. The company sells its products under the JustCBD, Vessel, Mind Naturals, Mambe, Stardog, Tonino Lamborghini, and Kalaya brands. Flora Growth Corp. was incorporated in 2019 and is headquartered in Toronto, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 59,505 -21.78% | 76,071 104.65% | 37,171 313.93% | |||
Cost of revenue | 70,504 | 78,928 | 56,463 | |||
Unusual Expense (Income) | ||||||
NOPBT | (10,999) | (2,857) | (19,292) | |||
NOPBT Margin | ||||||
Operating Taxes | (177) | (1,628) | (1,538) | |||
Tax Rate | ||||||
NOPAT | (10,822) | (1,229) | (17,754) | |||
Net income | (15,907) -72.11% | (57,036) 8.37% | (52,629) 146.38% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 7,502 | 2,738 | 4,296 | |||
BB yield | ||||||
| Debt | ||||||
Debt current | 2,871 | 3,529 | 2,274 | |||
Long-term debt | 4,849 | 2,683 | 4,926 | |||
Deferred revenue | ||||||
Other long-term liabilities | 856 | 3,547 | ||||
Net debt | 1,703 | 1,862 | (3,067) | |||
| Cash flow | ||||||
Cash from operating activities | (5,032) | (8,396) | (15,935) | |||
CAPEX | (134) | (163) | (1,294) | |||
Cash from investing activities | 203 | (234) | (15,802) | |||
Cash from financing activities | 6,494 | 3,150 | 4,413 | |||
FCF | (6,932) | 7,064 | (23,592) | |||
| Balance | ||||||
Cash | 6,017 | 4,350 | 9,537 | |||
Long term investments | 730 | |||||
Excess cash | 3,042 | 546 | 8,408 | |||
Stockholders' equity | (221) | (142,689) | (94,008) | |||
Invested Capital | 10,487 | 153,564 | 158,110 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 12,267 | 7,356 | 3,832 | |||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | (10,231) | (373) | (16,663) | |||
EV/EBITDA | ||||||
Interest | 213 | 92 | 56 | |||
Interest/NOPBT | ||||||